GlassScriptPhysician profile
Melissa Lynn Eigenbrode
NPI 1740784180
$4,648.57
in general payments reported to CMS, 2019-2025
32 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $963 · 2024: $2,185 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,648.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $950.42 | 2023-2025 | |
| Janssen Biotech, INC. | $688.81 | 2023-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $625.46 | 2023-2025 | Xifaxan, Plenvu, Trulance |
| Ardelyx, INC. | $361.49 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $359.89 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Intercept Pharmaceuticals, INC. | $321.99 | 2023-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $194.35 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $187.82 | 2023-2025 | |
| Qol Medical, LLC | $142.70 | 2024-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $95.32 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $81.95 | 2025 | Breztri, Fasenra, Tezspire |
| Phathom Pharmaceuticals, INC. | $76.61 | 2023-2025 | Voquezna |
| Madrigal Pharmaceuticals | $61.03 | 2025 | Rezdiffra |
| Celgene Corporation | $48.88 | 2023 | Zeposia |
| Pfizer INC. | $48.69 | 2024-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $43.74 | 2025 | Arikayce |
| Braintree Laboratories, INC. | $35.92 | 2023 | Sutab, Suflave |
| Aimmune Therapeutics, INC. | $32.17 | 2024 | |
| Mallinckrodt Hospital Products INC. | $27.44 | 2025 | Acthar |
| Verona Pharma, INC. | $25.78 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $24.34 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.96 | 2025 | Ofev |
| Ipsen Biopharmaceuticals, INC | $23.23 | 2024 | Iqirvo |
| Tactile Systems Technology INC | $22.82 | 2025 | Flexitouch Plus, Nimbl |
| Micro-Tech Endoscopy USA, INC. | $21.02 | 2023 | Sureclip |
| Glaxosmithkline, LLC. | $20.24 | 2025 | Nucala |
| Enterra Medical, INC. | $19.81 | 2023 | |
| Digestive Care, INC. | $18.63 | 2024 | Pertzye |
| Electromed, INC. | $18.43 | 2025 | Smartvest |
| Grifols USA, LLC | $16.50 | 2025 | Prolastin-C Liquid |
| Myriad Genetic Laboratories, INC. | $15.33 | 2025 | Myrisk |
| Amgen INC. | $13.80 | 2025 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Eigenbrode listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.